What this study is
This clinical trial tests an individually tailored, supervised, remote exercise intervention to improve physical function for stage I-III gastroesophageal cancer survivors. Modern treatments for gastroesophageal cancer are effective at treating the cancer but are often aggressive, can be difficult for patients to tolerate, and can lead to significant debilitation and a loss of independence. Exercise is one promising intervention that could improve physical function in patients with gastroesophageal cancer after finishing systemic treatment. Home based exercise interventions in patients with cancer during and after chemotherapy can improve fatigue and function. An individually tailored, supervised, remote exercise intervention may improve physical function for stage I-III gastroesophageal cancer survivors.
What's being tested
- Actigraphy
Intervention · OTHER
- Biospecimen Collection
Intervention · PROCEDURE
Undergo blood sample collection
- Educational Intervention
Intervention · OTHER
Receive written instructions
- Educational Intervention
Intervention · OTHER
Receive videos of strengthening exercises
- Electronic Health Record Review
Intervention · OTHER
- Exercise Intervention
Intervention · OTHER
Compete exercise sessions
- Internet-Based Intervention
Intervention · OTHER
Receive access to Moterum application
- Physical Performance Testing
Intervention · OTHER
- Survey Administration
Intervention · OTHER
All of Actigraphy, Electronic Health Record Review, Physical Performance Testing, Survey Administration
Ancillary studies
Study details
- Official title
- A Pilot Study of an Individually Tailored, Supervised, Remotely Delivered Exercise Intervention to Improve Physical Function in Survivors of Gastroesophageal Cancer (PRECISE Study)
- Sponsor
- Jonsson Comprehensive Cancer Center
- Conditions
- Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8 · Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8 · Clinical Stage I Gastric Cancer AJCC v8 · Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8 · Clinical Stage II Esophageal Adenocarcinoma AJCC v8 · Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8 · Clinical Stage II Gastric Cancer AJCC v8 · Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 · Clinical Stage III Esophageal Adenocarcinoma AJCC v8 · Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 · Clinical Stage III Gastric Cancer AJCC v8 · Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Enrolling
- 20 people
- Starts
- 2026-09-11
- Est. completion
- 2028-09-01
- Design
- Open-label, single group
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Adults ≥ 18 years old at the start of study treatment
- Diagnosis of early-stage (Stage I, II, III) esophageal, gastroesophageal junction, or gastric cancer. Histology can be adenocarcinoma, squamous cell carcinoma, or poorly differentiated carcinoma
- Treated with at least one systemic therapy (chemotherapy or immunotherapy) and within 12 months of completing curative intent gastroesophageal cancer (GEC) treatment
- Have evidence of physical function impairment, defined as a SPPB score of < 12) at baseline
- Ability to understand English and the willingness to sign a written informed consent document
You can't join if
- Patients with stage I disease who underwent endoscopic resection or surgery alone without perioperative systemic therapy
- Patients with stage IV disease or unresectable locally advanced disease taking a palliative treatment approach without a clearly defined end of treatment
- Patients currently receiving ongoing systemic therapy for GEC or another malignancy
- Patients who are unable to provide informed consent
- Any other condition or pre-existing co-morbidity that would, in the Investigator's judgment, contraindicate the participation in the study due to safety concerns with study procedures
- Currently participating in another exercise intervention research study seeking to improve functional status, alleviate frailty, muscle strength, exhaustion/fatigue, or cognitive function
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
- Jingran Ji, MD · Contact310-829-5471jingranji@mednet.ucla.edu
- Jingran Ji, MD · Principal investigator
Recruiting
Study team
Sponsor
Jonsson Comprehensive Cancer Center
Study ID 25-0954
Principal investigator
Jingran Ji, MD
UCLA / Jonsson Comprehensive Cancer Center
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.